3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
270
Observational
26
Expanded_access
1
Sponsor
Cancer Type
Myeloid
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Gynecologic
1
Conditions
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
15
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
10
Myelodysplastic Syndromes
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Recurrence
5
Lymphoma
5
Hematologic Neoplasms
5
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Immunologic Deficiency Syndromes
3
Blast Crisis
3
Waldenstrom Macroglobulinemia
2
Precancerous Conditions
2
Neoplasms
2
Multiple Myeloma
2
Mastocytosis, Systemic
2
Leukemia, Promyelocytic, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Mast-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Graft vs Host Disease
2
Congenital Abnormalities
2
Burkitt Lymphoma
2
Bone Marrow Failure Disorders
2
Thalassemia
1
Syndrome
1
Interventions
venetoclax
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Primary Myelofibrosis
×
Other hematologic neoplasm
×
Clear all
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available